Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom P Freeman

Showing results (91-100 of 196) with videos related to

Pageof 20
Sort By:
Neuroscience and Biobehavioral Reviews|November 25, 2021
Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?Kristine Rømer Thomsen, Birgitte Thylstrup, Emily A Kenyon, et al.
Neuroscience and Biobehavioral Reviews|October 4, 2019
How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic reviewAbigail M Freeman, Katherine Petrilli, Rachel Lees, et al.
Addiction (Abingdon, England)|February 11, 2025
Disentangling the effects of nicotine versus non-nicotine constituents of tobacco smoke on major depressive disorder: A multivariable Mendelian randomisation studyChloe Burke, Gemma Taylor, Tom P Freeman, et al.
Harm Reduction Journal|February 21, 2023
Legal sourcing of ten cannabis products in the Canadian cannabis market, 2019-2021: a repeat cross-sectional studyElle Wadsworth, Vicki Rynard, Pete Driezen, et al.
Psychopharmacology|May 14, 2009
Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humansTom P Freeman, Celia J A Morgan, Elissa Klaassen, et al.
Addiction (Abingdon, England)|June 25, 2016
Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysisMeryem Grabski, H Valerie Curran, David J Nutt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 24, 2014
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis usersChandni Hindocha, Tom P Freeman, Grainne Schafer, et al.
The International Journal on Drug Policy|December 24, 2025
Exploring THC labelling preferences to communicate the strength of cannabis products: Insights from U.S. consumersDanielle Dawson, Wayne Hall, Isabella Goodwin, et al.
Journal of Psychopharmacology (Oxford, England)|January 11, 2021
Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysisAbigail M Freeman, Claire Mokrysz, Chandni Hindocha, et al.
Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|December 28, 2023
Assessing the association between global structural brain age and polygenic risk for schizophrenia in early adulthood: A recall-by-genotype studyConstantinos Constantinides, Vilte Baltramonaityte, Doretta Caramaschi, et al.
Pageof 20

Showing results (91-100 of 196) with videos related to

Sort By:
Pageof 20
Neuroscience and Biobehavioral Reviews|November 25, 2021
Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?Kristine Rømer Thomsen, Birgitte Thylstrup, Emily A Kenyon, et al.
Neuroscience and Biobehavioral Reviews|October 4, 2019
How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic reviewAbigail M Freeman, Katherine Petrilli, Rachel Lees, et al.
Addiction (Abingdon, England)|February 11, 2025
Disentangling the effects of nicotine versus non-nicotine constituents of tobacco smoke on major depressive disorder: A multivariable Mendelian randomisation studyChloe Burke, Gemma Taylor, Tom P Freeman, et al.
Harm Reduction Journal|February 21, 2023
Legal sourcing of ten cannabis products in the Canadian cannabis market, 2019-2021: a repeat cross-sectional studyElle Wadsworth, Vicki Rynard, Pete Driezen, et al.
Psychopharmacology|May 14, 2009
Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humansTom P Freeman, Celia J A Morgan, Elissa Klaassen, et al.
Addiction (Abingdon, England)|June 25, 2016
Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysisMeryem Grabski, H Valerie Curran, David J Nutt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 24, 2014
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis usersChandni Hindocha, Tom P Freeman, Grainne Schafer, et al.
The International Journal on Drug Policy|December 24, 2025
Exploring THC labelling preferences to communicate the strength of cannabis products: Insights from U.S. consumersDanielle Dawson, Wayne Hall, Isabella Goodwin, et al.
Journal of Psychopharmacology (Oxford, England)|January 11, 2021
Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysisAbigail M Freeman, Claire Mokrysz, Chandni Hindocha, et al.
Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|December 28, 2023
Assessing the association between global structural brain age and polygenic risk for schizophrenia in early adulthood: A recall-by-genotype studyConstantinos Constantinides, Vilte Baltramonaityte, Doretta Caramaschi, et al.
Pageof 20